Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL St

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Finland , United States , Ukraine , Canada , America , American , John Fraunces , Chris Giordano , Brian Mullen , Tenax Therapeutics Inc , Nasdaq , Orion Corporation , Company Phase , Nasdaq Stock Market , Drug Administration , Lifesci Advisors , Therapeutics Enrolls First Patient , Oral Levosimendan , Pulmonary Hypertension , Heart Failure , Preserved Ejection Fraction , Exercise Limitation , Chief Executive Officer , North American , North America , Stuart Rich , Chief Medical Officer , Tenax Therapeutic Phase , Tenax Therapeutic , Sci Advisors ,